These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 14583580)

  • 21. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab).
    Li Gobbi F; Benucci M; Del Rosso A
    J Clin Rheumatol; 2005 Apr; 11(2):119-20. PubMed ID: 16357717
    [No Abstract]   [Full Text] [Related]  

  • 22. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
    [No Abstract]   [Full Text] [Related]  

  • 23. Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions.
    Taylor PC; Williams RO; Maini RN
    Curr Dir Autoimmun; 2000; 2():83-102. PubMed ID: 11791460
    [No Abstract]   [Full Text] [Related]  

  • 24. [Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab].
    D'Alessandro G; Bianco MR; Politis S; Ferrandina C; Rossi G; Altomare E
    Reumatismo; 2006; 58(1):59-61. PubMed ID: 16639489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-TNF therapy: safety aspects of taking the risk.
    Rosenblum H; Amital H
    Autoimmun Rev; 2011 Jul; 10(9):563-8. PubMed ID: 21570495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pseudolymphomatoid cutaneous leishmaniasis in a patient treated with adalimumab for rheumatoid arthritis.
    Baltà-Cruz S; Alsina-Glbert M; Mozos-Rocafort A; Cervera C; Colomo-Saperas L; Del Río A; Estrach-Panella T
    Acta Derm Venereol; 2009; 89(4):432-3. PubMed ID: 19688168
    [No Abstract]   [Full Text] [Related]  

  • 27. [Efficacy and adverse reactions of the TNFalpha inhibitor infliximab in rheumatoid arthritis].
    Imagama T; Taguchi T
    Nihon Rinsho; 2013 Jul; 71(7):1209-13. PubMed ID: 23961668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
    Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract]   [Full Text] [Related]  

  • 29. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 30. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atypical cutaneous tuberculosis in a patient with rheumatoid arthritis treated with infliximab.
    Asano Y; Kano Y; Shiohara T
    Acta Derm Venereol; 2008; 88(2):183-4. PubMed ID: 18311458
    [No Abstract]   [Full Text] [Related]  

  • 34. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors.
    Kim YJ; Kim YG; Shim TS; Koo BS; Hong S; Lee CK; Yoo B
    Rheumatology (Oxford); 2014 Aug; 53(8):1477-81. PubMed ID: 24681840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis.
    Geraghty EM; Ristow B; Gordon SM; Aronowitz P
    Clin Infect Dis; 2007 May; 44(10):e82-4. PubMed ID: 17443458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optic neuritis after infliximab therapy.
    Faillace C; de Almeida JR; de Carvalho JF
    Rheumatol Int; 2013 Apr; 33(4):1101-3. PubMed ID: 22198693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
    Ehlers S
    J Rheumatol Suppl; 2005 Mar; 74():35-9. PubMed ID: 15742463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment.
    Denis B; Lefort A; Flipo RM; Tubach F; Lemann M; Ravaud P; Salmon D; Mariette X; Lortholary O;
    Clin Microbiol Infect; 2008 Feb; 14(2):183-6. PubMed ID: 18076664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
    Koike R; Takeuchi T; Eguchi K; Miyasaka N;
    Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.